Dear Reader,
Gold keeps hitting all-time high after all-time high.
Gold bugs are out celebrating. And they should be.
But our gold expert Sean Brodrick saw this coming a long time ago.
In fact, he called gold's run into the $4,000s with uncanny precision.
Yet he's actually excited about something else that could do much, MUCH better than gold's next surge.
You see, every time gold has a big run, one type of stock goes absolutely crazy.
For instance, when this happened in the 2000s, gold rose 454%.
Meanwhile, some stocks saw gains like 5,090%, 7,746%, 9,850% and more.
In fact, our team identified 98 different stocks that delivered gains of at least 1,000%.
The most important part?
Now, Sean thinks we're in the early stages of the biggest bull market in gold yet.
He's actually found five companies that he believes could deliver the most explosive gains.
But the window won't stay open long …
Because when gold moves this fast, these stocks have moved even faster.
See how to access Sean's five top picks to benefit from this gold surge.
Eliza Lasky
Weiss Advocate
A Fresh IPO That Long-Term Investors Shouldn't Ignore
Reported by Jordan Chussler. Date Posted: 1/14/2026.
Summary
- While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful may offer considerable short-term upside potential.
Of course, IPOs also carry substantial downside risk. But even conservative investors who favor caution should not automatically dismiss newly listed companies — some may warrant a place in buy-and-hold portfolios.
Nearly $5,000 gold is nice ... but here's what most gold bugs are missing (Ad)
Gold recently broke past nearly $5,000, but one analyst is excited about something else that could do much better. Every time gold has a big run, certain stocks go absolutely crazy. During the 2000s gold rally, gold itself rose 454 percent. But some stocks delivered gains of 5,090, 7,746, and 9,850 percent. In fact, 98 different stocks hit at least 1,000 percent gains during that period. Now we may be in the early stages of the biggest gold bull market yet, and five companies have been identified with explosive potential.
Discover these five picks before the window closes.One biotechnology company in the healthcare sector that recently went public could fit that description.
Last Year’s IPO Success Stories
Last year shows why newly public companies deserve a second look, even from investors with lower risk tolerance.
AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. While short-term speculators may have captured its nearly 359% gain within its first 30 days on the Nasdaq, longer-term holders are still enjoying strong returns.
Other examples, such as Medline (NASDAQ: MDLN), counter the notion that IPOs are only risky startups. The medical products and services provider, which publicly debuted in December 2025, was founded in 1966 and already has a market cap above $55 billion.
Likewise, Smithfield Foods (NASDAQ: SFD)—known for its widely sold bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it attractive to income investors.
After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond.
Why Are Radiopharmaceuticals Important?
Aktis Oncology specializes in radiopharmaceuticals—a branch of nuclear medicine that uses radioactive drugs for diagnostics and treatment of conditions including cancer, heart disease and neurological disorders.
Radiopharmaceuticals pair radioactive isotopes with a targeting module that seeks out specific cells (for example, cancer cells) to deliver localized radiation doses. This approach aims to minimize damage to healthy tissue compared with conventional radiation therapies.
Industry consultancy Grand View Research estimates the global nuclear medicine market at nearly $18 billion in 2024 and forecasts growth to almost $35 billion by 2030, a compound annual growth rate of about 10.16%.
For Boston-based Aktis Oncology, the North American segment is particularly important: Grand View Research notes it accounts for nearly 43% of the global nuclear medicine market, with the United States as the dominant market.
Aktis Oncology’s Clinical-Stage Profile
Wall Street is expecting biotech IPO activity to rebound in 2026 after funding cuts in 2025 slowed listings from the healthcare sector.
Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised one of the largest sums for a biotech listing in recent memory. The IPO brought in $318 million and the company now has a market cap of about $3.34 billion.
According to the company’s prospectus, the executive team includes experienced drug developers and commercial leaders, with management having participated in bringing 14 currently FDA-approved products to market.
At a program level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer treatments that uses proprietary technology to target solid tumors while sparing healthy tissue.
Aktis Oncology’s Eli Lilly Connection
Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting a major pharmaceutical partner: Eli Lilly (NYSE: LLY), which anchored the IPO.
According to Reuters, Eli Lilly purchased $100 million of AKTS shares in the offering. That investment builds on a 2024 partnership in which Eli Lilly committed $60 million in cash and an equity investment to support the development of tumor-targeting radiopharmaceuticals, with potential milestone payments exceeding $1 billion.
The significance of Eli Lilly’s backing is notable. At about $1.01 trillion in market cap, Lilly is among Big Pharma’s largest companies, helped by a near 109% year-over-year jump in net income from 2023 to 2024. That momentum is expected to be reflected when Eli Lilly reports Q4 and full-year 2025 financials on Feb. 5.
Between its strategic partnership, equity stake and the recent $100 million share purchase, the maker of Zepbound has a meaningful financial interest in Aktis’ future success.
This email communication is a sponsored email from Weiss Ratings, a third-party advertiser of DividendStocks.com and MarketBeat.
11780 US Highway 1,
Palm Beach Gardens, FL 33408-3080
Would you like to edit your e-mail notification preferences or unsubscribe from our mailing list?
If you have questions about your account, please email MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. USA..